Categories
Publications & Presentations
Discover the main highlights of our industry in our latest publications.
Access to Care
Discover a complete record of access to care issues by region and PPTA activities in support of access to therapies.
Safety & Quality
Learn more about the regulatory policies and the Association’s voluntary standards for safety & quality standards.
Plasma Collection & Manufacturing
Learn more about plasma collection and discover certified plasma centers near you.
The Source Magazine
Subscribe to the international magazine of the plasma protein therapeutics industry.
Plasma FAQS
Get answers about plasma therapies and the processes surrounding donation and collection procedures.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Mar 16, 2020
Plasma-Derived Therapies Provide Significant Health Value Gain
New report analyses clinical, economic, and societal perspectives for patient access.
All
Press releases
Mar 16, 2020
Plasma-Derived Therapies Provide Significant Health Value Gain
New report analyses clinical, economic, and societal perspectives for patient access.
All
Press releases
Mar 16, 2020
A Note to U.S. Plasma Donors on the Spread of Coronavirus
At this time of global concern regarding spread of the novel coronavirus, PPTA wants to thank the millions of committed plasma donors who make lifesaving medicines for rare disease patients a reality and to remind them that donor safety continues to be a top priority for PPTA and its member companies.
All
PPTA statements
Mar 16, 2020
A Note to U.S. Plasma Donors on the Spread of Coronavirus
At this time of global concern regarding spread of the novel coronavirus, PPTA wants to thank the millions of committed plasma donors who make lifesaving medicines for rare disease patients a reality and to remind them that donor safety continues to be a top priority for PPTA and its member companies.
All
PPTA statements
Mar 5, 2020
Key Economic & Value Considerations for PDMPs in Europe
PDMPs constitute several classes of biologic therapies, i.e. clotting factors, immunoglobulins (IgGs, including hyperimmune globulins), alpha-1 proteinase inhibitors, albumin and C1-esterase inhibitors. PDMPs share a unique nature: they are derived from human biologic material (plasma) and have a highly complex and regulated manufacturing process.
All
Publication
https://www.vintura.com/news/white-paper-key-economic-value-considerations-plasma-derived-medicinal-products-pdmps-europe/
Mar 5, 2020
Key Economic & Value Considerations for PDMPs in Europe
PDMPs constitute several classes of biologic therapies, i.e. clotting factors, immunoglobulins (IgGs, including hyperimmune globulins), alpha-1 proteinase inhibitors, albumin and C1-esterase inhibitors. PDMPs share a unique nature: they are derived from human biologic material (plasma) and have a highly complex and regulated manufacturing process.
All
Publication
https://www.vintura.com/news/white-paper-key-economic-value-considerations-plasma-derived-medicinal-products-pdmps-europe/
Mar 1, 2020
The Source Spring 2020
Magazine of the plasma protein therapeutics industry - Spring 2020
All
The Source Magazine
https://cdn.prod.website-files.com/638f893112c6eac0e46ac576/644fcd85d7193fcbb083a194_The%20Source_Spring%202020.pdf
Mar 1, 2020
The Source Spring 2020
Magazine of the plasma protein therapeutics industry - Spring 2020
All
The Source Magazine
https://cdn.prod.website-files.com/638f893112c6eac0e46ac576/644fcd85d7193fcbb083a194_The%20Source_Spring%202020.pdf
No results found